Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atreca, Inc. stock logo
BCEL
Atreca
$0.09
$0.09
$0.05
$1.20
$3.57M1.034.61 million shsN/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
$0.43
$0.08
$3.32
$11.60M0.248.88 million shs1.16 million shs
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$29.44
+3.6%
$31.33
$24.10
$62.53
$2.66B0.25817,851 shs867,380 shs
XBiotech Inc. stock logo
XBIT
XBiotech
$3.22
+1.6%
$2.86
$2.50
$8.32
$96.65M0.9869,317 shs52,318 shs
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
$1.08
$0.77
$5.95
$187.12M1.712.01 million shs2.13 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atreca, Inc. stock logo
BCEL
Atreca
0.00%0.00%0.00%0.00%0.00%
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00%0.00%0.00%0.00%0.00%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-1.15%-8.11%-7.06%-9.43%-38.29%
XBiotech Inc. stock logo
XBIT
XBiotech
+6.73%+18.73%+11.62%+0.96%-42.88%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atreca, Inc. stock logo
BCEL
Atreca
N/AN/AN/AN/AN/AN/AN/AN/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.5845 of 5 stars
3.50.00.03.72.52.50.0
XBiotech Inc. stock logo
XBIT
XBiotech
0.632 of 5 stars
0.00.00.00.03.52.50.6
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atreca, Inc. stock logo
BCEL
Atreca
0.00
N/AN/AN/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00
N/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.90
Moderate Buy$71.75143.72% Upside
XBiotech Inc. stock logo
XBIT
XBiotech
0.00
N/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ZIOP, XBIT, CRNX, BCEL, and CLVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atreca, Inc. stock logo
BCEL
Atreca
N/AN/AN/AN/A$2.01 per shareN/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
$148.76M0.00N/AN/A($2.15) per share0.00
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$1.04M2,650.45N/AN/A$14.29 per share2.06
XBiotech Inc. stock logo
XBIT
XBiotech
$4.01M24.48N/AN/A$5.98 per share0.54
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A$0.58 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atreca, Inc. stock logo
BCEL
Atreca
-$97.16M-$2.50N/AN/AN/AN/A-157.90%-71.39%N/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
-$264.52M-$1.83N/AN/AN/A-189.37%N/A-57.78%N/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)
XBiotech Inc. stock logo
XBIT
XBiotech
-$38.53M-$1.29N/AN/AN/A-21.14%-19.55%8/11/2025 (Estimated)
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/A

Latest ZIOP, XBIT, CRNX, BCEL, and CLVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
XBiotech Inc. stock logo
XBIT
XBiotech
N/A-$0.36N/A-$0.36N/AN/A
5/8/2025Q1 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atreca, Inc. stock logo
BCEL
Atreca
N/AN/AN/AN/AN/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atreca, Inc. stock logo
BCEL
Atreca
N/A
1.58
1.58
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A
0.14
0.12
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
22.53
22.53
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
29.15
29.15
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.18
3.43
3.43

Institutional Ownership

CompanyInstitutional Ownership
Atreca, Inc. stock logo
BCEL
Atreca
37.47%
Clovis Oncology stock logo
CLVS
Clovis Oncology
24.53%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
51.03%

Insider Ownership

CompanyInsider Ownership
Atreca, Inc. stock logo
BCEL
Atreca
11.30%
Clovis Oncology stock logo
CLVS
Clovis Oncology
4.40%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
4.60%
XBiotech Inc. stock logo
XBIT
XBiotech
33.10%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atreca, Inc. stock logo
BCEL
Atreca
13039.62 million35.15 millionOptionable
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A144.96 million138.58 millionOptionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
21093.63 million89.32 millionOptionable
XBiotech Inc. stock logo
XBIT
XBiotech
10030.49 million20.40 millionOptionable
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
105216.15 million204.91 millionOptionable

Recent News About These Companies

Best Global Universities for Oncology
FDA fast-tracks Merck's cancer blockbuster-in-waiting
Childhood Cancers
Alx Oncology Holdings (ALXO)
Pediatric Hematology-Oncology Fellowship
CG Oncology Inc
Immuno-Oncology
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
Association of Community Cancer Centers
Oncology News and Research
WBSPH 2024 - Oncology
Kris on Oncology
Oncology Cases & Quizzes

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atreca stock logo

Atreca NASDAQ:BCEL

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Clovis Oncology stock logo

Clovis Oncology NASDAQ:CLVS

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$29.44 +1.01 (+3.55%)
Closing price 04:00 PM Eastern
Extended Trading
$29.45 +0.01 (+0.03%)
As of 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$3.22 +0.05 (+1.58%)
Closing price 04:00 PM Eastern
Extended Trading
$3.22 0.00 (0.00%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

ZIOPHARM Oncology stock logo

ZIOPHARM Oncology NASDAQ:ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.